Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBOHB Ophthalmic Compound for Presbyopia
NCT05006911Phase 1Unknown
- Sponsor
- Optall Vision
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pilocarpine, brimonidine, oxymetazoline, hyaluronic acid and bromfenac sodium in presbyopia, sponsored by Optall Vision. Primary endpoint: Jaeger near uncorrected visual acuity improvement at 1 hour. Status: unknown.
02
Drugs
pilocarpinebrimonidineoxymetazolinehyaluronic acidbromfenac sodium
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05006911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006911.